An Open Label, Randomized, Two Part Study to Evaluate the CYP2C8- and OATP1B1-Mediated Drug-Drug Interaction Potential of GSK1278863 With Pioglitazone and Rosuvastatin as Victims and Trimethoprim as Perpetrator in Healthy Adult Volunteers

Trial Profile

An Open Label, Randomized, Two Part Study to Evaluate the CYP2C8- and OATP1B1-Mediated Drug-Drug Interaction Potential of GSK1278863 With Pioglitazone and Rosuvastatin as Victims and Trimethoprim as Perpetrator in Healthy Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 15 May 2017

At a glance

  • Drugs Daprodustat (Primary) ; Pioglitazone (Primary) ; Rosuvastatin (Primary) ; Trimethoprim (Primary)
  • Indications Anaemia
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 11 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 19 Apr 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 27 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top